Demand For A/H1N1 Vaccine Catapults Green Cross Into No. 2 Spot In Korea; Company Ramps Up Biosimilar Pipeline
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Of the many local Korean pharmaceutical players, vaccine producer Green Cross was the biggest beneficiary of the A/H1N1 flu pandemic last year as increased demand for its vaccines triggered a remarkable upgrade in its rankings to the second-largest from its previous long-time position of No. 5
You may also be interested in...
Korea’s Green Cross Anticipates Growth In Upcoming Flu Season
The upcoming flu season should provide more momentum to Korea’s leading vaccine company, which saw marginal year-on-year growth in the second quarter.
Dong-A Enrolls GSK Korea General Manager On Board Of Directors; GSK Says Move Will Strengthen Alliance, Not Influence
SEOUL - Korea's leading pharma Dong-A Pharmaceutical Co. Ltd. placed GlaxoSmithKline PLC's Korea General Manager Kim Jin-ho on its nine-member board of directors in a follow-up action to GSK's acquisition of a 9.9% stake in Dong-A in May 2010
Dong-A Enrolls GSK Korea General Manager On Board Of Directors; GSK Says Move Will Strengthen Alliance, Not Influence
SEOUL - Korea's leading pharma Dong-A Pharmaceutical Co. Ltd. placed GlaxoSmithKline PLC's Korea General Manager Kim Jin-ho on its nine-member board of directors in a follow-up action to GSK's acquisition of a 9.9% stake in Dong-A in May 2010